Drugs / HS-20110
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT06892379 | Feb 2025 → Dec 2026 expected | cancer | Hansoh BioMedical R&D Company | Recruiting | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT07283367 | Dec 2025 → Dec 2029 expected | — | Hansoh BioMedical R&D Company | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | HS-20110 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06892379 ↗ |
| Route | Intravenous | “HS-20110 for IV infusion of various dose strengths administered in 21 day dosing cycles” NCT06892379 ↗ |